Mode
Text Size
Log in / Sign up

Two doses of SARS-CoV-2 vaccine show protective effect against MIS-C in childrenTwo vaccine doses linked to lower MIS-C risk in children

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Two SARS-CoV-2 vaccine doses significantly protect children against MIS-C after infection, per a limited systematic review.

A systematic review of observational studies examined the association between SARS-CoV-2 vaccination and the incidence of multisystem inflammatory syndrome in children (MIS-C) following infection. The analysis compared children who received one or two vaccine doses with unvaccinated or partially vaccinated peers. The primary focus was on the protective effect of vaccination against MIS-C development.

The review included six studies from an initial pool of 944 identified records. This limited number of included studies reflects the current evidence base. The main finding was a significant protective effect for children who received two doses of a SARS-CoV-2 vaccine, with a reported effect size of d=0.71 and a 95% confidence interval of 0.07 to 1.35 (p=0.03). For one dose, a protective trend was observed, but it was not statistically significant.

The evidence supports a protective effect of two vaccine doses, but certainty is limited by the small number of included studies and potential bias. The review did not report on vaccine safety outcomes. It is important to note that this analysis reports an association, not causation, as it is based on observational data.

Clinicians can use this evidence to advocate for continued vaccination of children against SARS-CoV-2. The findings are specific to the studied populations and should not be extrapolated to other groups. The review underscores the importance of vaccination in preventing severe outcomes like MIS-C.

This systematic review looked at studies on children with SARS-CoV-2 infection to see how vaccination affected their risk of developing multisystem inflammatory syndrome, or MIS-C. The review included six studies and focused on children who received one or two doses of a SARS-CoV-2 vaccine compared to those who were unvaccinated or partially vaccinated.

The main finding was that two vaccine doses showed a significant protective effect against MIS-C after infection. A single dose showed a trend toward protection, but it was not statistically significant. The review did not report specific numbers of children affected or detailed safety data.

The evidence is based on observational studies, so it shows a link but cannot prove the vaccine causes the lower risk. The certainty of the evidence is limited because only a few studies were included and some potential bias was noted.

The main reason to be careful is that this is a review of a small number of studies, and the results may not apply to all children. Readers should understand that this supports vaccination but does not provide new safety data or change current medical advice.

What this means for you:
Two vaccine doses are linked to a lower MIS-C risk in infected children, but the evidence is limited.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
Multisystem inflammatory syndrome in children (MIS-C) is a rare but serious condition associated with pediatric SARS-CoV-2 infection. While COVID-19 vaccines prevent infection and reduce severity, less conclusive evidence exists regarding their role in preventing MIS-C during breakthrough infections. This systematic review assessed the impact of SARS-CoV-2 vaccination on MIS-C risk during breakthrough infection. Cross-sectional studies, surveillance studies, and cohort studies were included. Of the 944 studies identified, 6 were included. A significant protective effect was seen in patients who received two doses of SARS-CoV-2 vaccination after exclusion of a biased sample (d= 0.71 [95% CI 0.07 to 1.35; p=0.03]). A trend towards a protective effect was seen after one dose of vaccination, but this effect was not statistically significant. Current literature supports a protective effect of two doses of SARS-CoV-2 vaccination against development of MIS-C in breakthrough COVID-19. The evidence supports clinician advocacy for continued vaccination of children against SARS-CoV-2.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.